Photo via Pexels
CRISPR-Cas13 is a distinct CRISPR enzyme that, unlike Cas9, targets RNA rather than DNA, offering a powerful tool for modulating gene expression or degrading viral RNA. This system can be programmed with guide RNAs to specifically recognize and cleave viral RNA genomes or host mRNAs involved in viral replication, effectively halting infection. Pioneering research is being conducted by institutions like the Broad Institute of MIT and Harvard, UC San Francisco, and Mammoth Biosciences. The technology is primarily in advanced research and preclinical development stages, with promising results in cell cultures and animal models. For example, in a 2023 study published in Cell, researchers demonstrated that Cas13-based therapies could effectively inhibit replication of SARS-CoV-2 and influenza viruses in lung cells and mice. This offers a highly specific and potentially broad-spectrum antiviral strategy, sidestepping issues of drug resistance common with small-molecule antivirals.
Editorial check
How this page is checked
Source trail
broadinstitute.org
External links are separated from Surfaced commentary.
Reader safety
Context before clicks
Product links and external services are not presented as guarantees.
Monetization
No affiliate flag
Ads and commerce links are kept distinct from editorial text.
Surfaced take
Why It Matters
Viral pandemics and endemic infections (e.g., influenza, HIV, future novel viruses) pose immense global health threats, causing millions of deaths and trillions in economic losses annually. RNA-targeted CRISPR-Cas13 could provide a rapid-response, adaptable antiviral platform to combat current and emerging viral threats, potentially preventing future pandemics. Biotech companies like Mammoth Biosciences and other gene therapy developers would gain a significant advantage, while traditional pharmaceutical companies focused on small-molecule antivirals might face increased competition. Key technical challenges include efficient and safe delivery of the Cas13 system to target cells in vivo, and avoiding off-target RNA cleavage; regulatory pathways for RNA-editing therapies are still evolving. Initial clinical trials for specific viral diseases could begin in 5-10 years, with widespread therapeutic use in 15-20 years. The US, Europe, and China are significant players in CRISPR research. A second-order consequence could be a shift towards 'on-demand' programmable therapeutics, where treatments are designed and deployed rapidly in response to new pathogen outbreaks.
Development Stage
Related
Scrintal
Scrintal is a visual knowledge canvas and note-taking tool developed by a startup, designed to help users think spatially and connect ideas on an infinite…
Have I Been Pwned (HIBP)
Have I Been Pwned (HIBP) is a free online service created by security expert Troy Hunt, designed to help people check if their email addresses or phone numbers…
Enjoyed this? Get five picks like this every morning.
Free daily newsletter — zero spam, unsubscribe anytime.